Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial.
Zhang D, Benedikt Westphalen C, Quante M, Waldschmidt DT, Held S, Kütting F, Dorman K, Heinrich K, Weiss L, Boukovala M, Haas M, Boeck S, Heinemann V, Probst V. Zhang D, et al. Among authors: waldschmidt dt. Eur J Cancer. 2024 Apr;201:113926. doi: 10.1016/j.ejca.2024.113926. Epub 2024 Feb 15. Eur J Cancer. 2024. PMID: 38401449 Free article. Clinical Trial.
Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
Weiss L, Heinemann V, Fischer LE, Gieseler F, Hoehler T, Mayerle J, Quietzsch D, Reinacher-Schick A, Schenk M, Seipelt G, Siveke JT, Stahl M, Vehling-Kaiser U, Waldschmidt DT, Dorman K, Zhang D, Westphalen CB, von Bergwelt-Baildon M, Boeck S, Haas M. Weiss L, et al. Among authors: waldschmidt dt. Clin Transl Oncol. 2024 May;26(5):1268-1272. doi: 10.1007/s12094-023-03323-1. Epub 2023 Oct 4. Clin Transl Oncol. 2024. PMID: 37794220 Free PMC article.
Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence.
Lyu SI, Fretter C, Simon AG, Spielmann SM, Damanakis AI, Zhao Y, Bruns CJ, Schmidt T, Popp FC, Waldschmidt D, Quaas A, Knipper K; PANCALYZE Study Group. Lyu SI, et al. Transl Oncol. 2024 Sep;47:102044. doi: 10.1016/j.tranon.2024.102044. Epub 2024 Jun 24. Transl Oncol. 2024. PMID: 38917592 Free PMC article.
Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315).
Ettrich TJ, Modest DP, Sinn M, Striefler JK, Opitz B, Goetze T, Gallmeier E, Angermeier S, Fischer von Weikersthal L, Jacobasch L, Waldschmidt D, Niedermeier M, Sohm M, Berger AW, Manzini G, Fehrenbach U, Auer TA, Hosse C, Vogele D, Sookthai D, Schaaf M, Muche R, Hinke A, Seufferlein T, Perkhofer L. Ettrich TJ, et al. J Clin Oncol. 2024 Sep 10;42(26):3094-3104. doi: 10.1200/JCO.23.01566. Epub 2024 Jun 6. J Clin Oncol. 2024. PMID: 38843469 Free PMC article. Clinical Trial.
Therapy-relevant MDM2 amplification in cholangiocarcinomas in Caucasian patients.
Lyu SI, Plum PS, Fretter C, Simon AG, Bedau T, Knipper K, Thomas MN, Stippel D, Wagner BJ, Bruns C, Waldschmidt D, Büttner R, Drebber U, Quaas A. Lyu SI, et al. Ther Adv Med Oncol. 2024 Nov 9;16:17588359241288123. doi: 10.1177/17588359241288123. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39525665 Free PMC article.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort.
Mitzlaff K, Kirstein MM, Müller C, Venerito M, Olkus A, Dill MT, Weinmann A, Kocheise L, Busch A, Schulze K, Allo G, Waldschmidt DT, Barsch M, Bengsch B, Quante M, Gonzalez-Carmona MA, Himmelsbach V, Finkelmeier F, Kloeckner R, Schirmacher P, Marquardt JU, Zimpel C. Mitzlaff K, et al. Among authors: waldschmidt dt. United European Gastroenterol J. 2024 Nov;12(9):1230-1242. doi: 10.1002/ueg2.12656. Epub 2024 Sep 20. United European Gastroenterol J. 2024. PMID: 39301763 Free PMC article.
Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group.
Weiss L, Fischer LE, Heinemann V, Gieseler F, Hoehler T, Mayerle J, Quietzsch D, Reinacher-Schick A, Schenk M, Seipelt G, Siveke JT, Stahl M, Kaiser U, Waldschmidt DT, Dorman K, Zhang D, Westphalen CB, Boeck S, Haas M. Weiss L, et al. Among authors: waldschmidt dt. ESMO Open. 2024 Apr;9(4):102944. doi: 10.1016/j.esmoop.2024.102944. Epub 2024 Mar 18. ESMO Open. 2024. PMID: 38503144 Free PMC article.
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report.
Reutter T, Fassunke J, Püsken M, Weber JP, Binot E, Eisert A, Fischer R, Nogova L, Riedel R, Schaufler D, Scharpenseel H, Scheffler M, Schulz H, Waldschmidt DT, Zander T, Merkelbach-Bruse S, Schirmacher P, Büttner R, Wolf J, Michels S. Reutter T, et al. Among authors: waldschmidt dt. JCO Precis Oncol. 2023 Apr;7:e2200467. doi: 10.1200/PO.22.00467. JCO Precis Oncol. 2023. PMID: 37079858 No abstract available.
22 results